Despite significant advances in the treatment of asthma, optimal clinical therapy for patients with this increasingly common and potentially debilitating disease is still in flux. Blacks and children bear a disproportionate burden of asthma morbidity and we are unable to stop the development and the progression of the disease in children. Several lines of evidence, including a recent FDA analysis, suggest that Blacks may experience increased serious adverse effects when using long-acting beta agonists (LABAs). Our retrospective analysis of the recently completed ACRN LARGE trial suggested that homozygosity at the 16th amino acid position of the beta2-adrenergic receptor (B16 Arg/Arg) identifies a group of patients among Blacks that experience decreased benefit from LABA added to an inhaled corticosteroid (LABA/ICS). Our first trial, which includes both adults and children, prospectively examines whether B16 Arg/Arg identifies a group of Blacks who experience only marginal benefit from adding LABA to ICS therapy. Since 20% of Blacks are B16 Arg/Arg, this finding could alter therapy for a large proportion of the Black community. Our second proposal examines whether we can modify asthma in children. No current therapies available are able to produce long-lasting effects in asthma. Asthma in children is associated with a marked increase in IgE-mediated allergic sensitization in school-age children. Anti-IgE therapy has the potential to prevent allergic sensitization in these children and thus to alter the progression of disease. We therefore propose treating early school-age children with anti-IgE. In addition to examining outcomes during treatment, we will follow them for two years after cessation of therapy. In our mechanistic study of our anti-IgE proposal, we will explore how anti-IgE therapy may reprogram immune cells in the children participating in the trial. Airway inflammation is central to the pathobiology of asthma. In our proof of concept study we will examine whether newly discovered compounds that the body naturally produces to counter inflammation-resolvins, can be used to down regulate airway inflammation in allergic asthmatics exposed to allergens.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Special Emphasis Panel (ZHL1-CSR-U (S1))
Program Officer
Taggart, Virginia
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Kanchongkittiphon, Watcharoot; Mendell, Mark J; Gaffin, Jonathan M et al. (2015) Indoor environmental exposures and exacerbation of asthma: an update to the 2000 review by the Institute of Medicine. Environ Health Perspect 123:20-Jun
Permaul, Perdita; Kanchongkittiphon, Watcharoot; Phipatanakul, Wanda (2014) Childhood asthma and obesity--what is the true link? Ann Allergy Asthma Immunol 113:244-6
Sutherland, E Rand; Busse, William W; National Heart, Lung, and Blood Institute's AsthmaNet (2014) Designing clinical trials to address the needs of childhood and adult asthma: the National Heart, Lung, and Blood Institute's AsthmaNet. J Allergy Clin Immunol 133:34-8.e1
Huffaker, Michelle; Phipatanakul, Wanda (2014) Introducing an environmental assessment and intervention program in inner-city schools. J Allergy Clin Immunol 134:1232-7
Castro, Mario; King, Tonya S; Kunselman, Susan J et al. (2014) Effect of vitamin D3 on asthma treatment failures in adults with symptomatic asthma and lower vitamin D levels: the VIDA randomized clinical trial. JAMA 311:2083-91
Gaffin, Jonathan M; Kanchongkittiphon, Watcharoot; Phipatanakul, Wanda (2014) Perinatal and early childhood environmental factors influencing allergic asthma immunopathogenesis. Int Immunopharmacol 22:21-30
Kanchongkittiphon, Watcharoot; Gaffin, Jonathan M; Phipatanakul, Wanda (2014) The indoor environment and inner-city childhood asthma. Asian Pac J Allergy Immunol 32:103-10
Wright, Lakiea S; Phipatanakul, Wanda (2014) Environmental remediation in the treatment of allergy and asthma: latest updates. Curr Allergy Asthma Rep 14:419
Szefler, Stanley J; Chmiel, James F; Fitzpatrick, Anne M et al. (2014) Asthma across the ages: knowledge gaps in childhood asthma. J Allergy Clin Immunol 133:3-13; quiz 14
Kantor, David B; Phipatanakul, Wanda (2014) Intravenous ? agonists and severe pediatric asthma exacerbation: time for a closer look at terbutaline? Ann Allergy Asthma Immunol 112:187

Showing the most recent 10 out of 20 publications